Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe

News Update


Biotech Partnership to Develop Diagnostic Assay for Alzheimer's Disease
News Update

Share on Stocktwits


With its work on this and a SARS-CoV-2 test, ProMIS Neurosciences is applying its technology platform in new ways.

ProMIS Neurosciences Inc. (PMN:TSX; ARFXF:OTCQB) and its partner, BC Neuroimmunology (BCNI), will collaborate to develop highly sensitive and specific assays for use in accurately screening for and diagnosing Alzheimer's disease, ProMIS announced in a news release.

"We intend to help address this very important unmet need by capitalizing on our existing portfolio of antibodies and antigens and applying these existing assets to BCNI's outstanding expertise in the development of high performance diagnostic tests," ProMIS Executive Chairman Eugene Williams said in the release.

The two companies state they intend to use surface plasmon resonance (SPR) technology, with which they both have extensive experience, to develop sensitive blood-based Alzheimer's disease diagnostic tests cheaply and quickly. ProMIS has a "unique, core technology to predict novel targets on the molecular surface of complex proteins."

Because significant advances have been made in the throughput and stability of SPR technology, it could replace ELISA, or enzyme-linked immunosorbent assay, as the new cost-effective standard, the release stated.

ProMIS and BCNI also are working on developing an SPR-based antibody assay designed to achieve 100% sensitivity and 99.9% specificity for the virus that causes COVID-19.

"At BCNI, we are developing high-throughput SPR tests in conjunction with ProMIS whose unique peptide antigens are anticipated to be a critical component for development and commercialization of top quality assays targeting infectious disease, such as COVID-19, and neurodegenerative disease, such as Alzheimer's," BCNI CEO Dr. Hans Frykman said in the release.


1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: ProMIS Neurosciences. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of ProMIS Neurosciences, a company mentioned in this article.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Want to read more about Life Sciences Tools & Diagnostics investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe